Jan Pruim
Overview
Explore the profile of Jan Pruim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glaudemans A, Dierckx R, Scheerder B, Niessen W, Pruim J, Dewi D, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(2):336-339.
PMID: 37962619
No abstract available.
2.
Koster T, Charbonnier J, Pruim J, Gietema H, Posthuma R, Vanfleteren L, et al.
Am J Respir Crit Care Med
. 2023 May;
208(4):495-498.
PMID: 37192444
No abstract available.
3.
Hustinx R, Pruim J, Lassmann M, Visvikis D
Eur J Nucl Med Mol Imaging
. 2022 Aug;
50(1):61-66.
PMID: 36006443
Artificial intelligence (AI) is coming into the field of nuclear medicine, and it is likely here to stay. As a society, EANM can and must play a central role in...
4.
Visvikis D, Lambin P, Beuschau Mauridsen K, Hustinx R, Lassmann M, Rischpler C, et al.
Eur J Nucl Med Mol Imaging
. 2022 Jul;
49(13):4452-4463.
PMID: 35809090
Artificial intelligence (AI) will change the face of nuclear medicine and molecular imaging as it will in everyday life. In this review, we focus on the potential applications of AI...
5.
Wedman J, Pruim J, van der Putten L, Hoekstra O, de Bree R, van Dijk B, et al.
Clin Otolaryngol
. 2018 Oct;
44(2):124-130.
PMID: 30315624
Objective: 18F FDG-PET is superior to other imaging techniques in revealing residual laryngeal cancer after radiotherapy. Unfortunately, its specificity is low, due to FDG uptake in inflammation and in anaerobic...
6.
Brahm C, den Hollander M, Enting R, de Groot J, Solouki A, den Dunnen W, et al.
Eur J Nucl Med Mol Imaging
. 2018 Jul;
45(13):2404-2412.
PMID: 30032322
Purpose: Response evaluation in patients with glioblastoma after chemoradiotherapy is challenging due to progressive, contrast-enhancing lesions on MRI that do not reflect true tumour progression. In this study, we prospectively...
7.
Wondergem M, van der Zant F, Knol R, Burgers A, Bos S, de Jong I, et al.
World J Urol
. 2017 Oct;
36(1):27-34.
PMID: 29043431
Introduction/aim: Correct staging of patients with prostate cancer is important for treatment planning and prognosis. Although bone scintigraphy with Tc-phosphonates (BS) is generally advised for staging by guidelines in high...
8.
Wondergem M, van der Zant F, Knol R, Lazarenko S, Pruim J, de Jong I
J Nucl Med
. 2017 Apr;
58(11):1797-1804.
PMID: 28450569
There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA) tracers for imaging of prostate cancer because of the higher detection rates of prostate cancer lesions than with PET/CT...
9.
Kerner G, Koole M, Bongaerts A, Pruim J, Groen H
PLoS One
. 2016 May;
11(5):e0149955.
PMID: 27137772
Background: In ALK-positive advanced NSCLC, crizotinib has a high response rate and effectively increases quality of life and survival. CT measurement of the tumor may insufficiently reflect the actual tumor...
10.
Kerner G, Bollineni V, Hiltermann T, Sijtsema N, Fischer A, Bongaerts A, et al.
EJNMMI Res
. 2016 Apr;
6(1):33.
PMID: 27090118
Background: Hypoxia is associated with resistance to chemotherapy and radiotherapy and is randomly distributed within malignancies. Characterization of changes in intratumoral hypoxic regions is possible with specially developed PET tracers...